GLPGF (Lakefront Biotherapeutics NV) ROCE %: -7.76% (As of Mar. 2026)


GLPGF Lakefront Biotherapeutics NV GLPGF
62 GF Score
Price $28.08
GF Value $136.98
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Lakefront Biotherapeutics NV ROCE %?

Lakefront Biotherapeutics NV GLPGF 62 ROCE % is -7.76% as of Mar. 2026. GuruFocus rates GLPGF with a GF Score™ of 62/100 and a GF Value™ of $136.98 (Possible Value Trap). The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Lakefront Biotherapeutics NV's annualized ROCE % for the quarter that ended in Mar. 2026 was -7.76%.

Lakefront Biotherapeutics NV  (OTCPK:GLPGF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Lakefront Biotherapeutics NV ROCE % Related Terms

Lakefront Biotherapeutics NV ROCE % Historical Data

* Premium members only.

The historical data trend for Lakefront Biotherapeutics NV's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lakefront Biotherapeutics NV ROCE % Chart

Lakefront Biotherapeutics NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.14 -1.35 0.18 -0.06 9.11

Lakefront Biotherapeutics NV Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -17.47 -11.94 0.30 69.99 -7.76
GLPGF
62GF Score
Lakefront Biotherapeutics NV GLPGF
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lakefront Biotherapeutics NV ROCE % Calculation

Lakefront Biotherapeutics NV's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=354.904/( ( (4330.596 - 350.87) + (3988.897 - 178.996) )/ 2 )
=354.904/( (3979.726+3809.901)/ 2 )
=354.904/3894.8135
=9.11 %

Lakefront Biotherapeutics NV's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-294.58/( ( (3988.897 - 178.996) + (3898.762 - 116.097) )/ 2 )
=-294.58/( ( 3809.901 + 3782.665 )/ 2 )
=-294.58/3796.283
=-7.76 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -7.76% mean?
Lakefront Biotherapeutics NV (GLPGF) has a ROCE % of -7.76% as of Mar. 2026.
Is Lakefront Biotherapeutics NV's ROCE % too high?
Lakefront Biotherapeutics NV's current ROCE % is -7.76%. Overall, Lakefront Biotherapeutics NV has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Lakefront Biotherapeutics NV's ROCE % compare to VRTX and REGN?
Lakefront Biotherapeutics NV's ROCE % of -7.76% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Lakefront Biotherapeutics NV's current ROCE % is -7.76%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lakefront Biotherapeutics NV stock overvalued right now?
Based on GuruFocus' analysis, Lakefront Biotherapeutics NV (GLPGF) is currently considered Possible Value Trap. The stock's GF Value™ is $136.98, compared to a current price of $28.08 — trading 79.5% below its estimated fair value. The current ROCE % is -7.76%. Lakefront Biotherapeutics NV's overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Lakefront Biotherapeutics NV (GLPGF), the current ROCE % is -7.76% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lakefront Biotherapeutics NV (GLPGF) Overvalued in 2026?

Based on GuruFocus' analysis, Lakefront Biotherapeutics NV stock appears to be undervalued. The current stock price of $28.08 is trading 79.5% below its estimated GF Value™ of $136.98. GuruFocus considers Lakefront Biotherapeutics NV to be Possible Value Trap.

Key valuation signals for GLPGF:

  • ROCE %: -7.76%
  • GF Value™: $136.98 vs. price of $28.08 (79.5% below fair value)
  • GF Score™: 62/100 with 4 warning signs

No single metric tells the full story. See the GLPGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lakefront Biotherapeutics NV Business Description

Address Schalienhoevedreef 20 T, Mechelen, BEL, 2800
Lakefront Biotherapeutics NV a biopharmaceutical company committed to improving the lives of people with severe diseases. It focuses on delivering medicines with transformational impact for patients by accelerating life-changing science and innovation in areas of high unmet need. Its pipelines includes GLPG3667, GLPG5101, and GLPG5301.
62GF Score

Get the complete analysis for GLPGF

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$28.08
Price
$136.98
GF Value